Clinical Trials
9 trialsNCT06161532 2026-06-05
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03725761 2026-06-04
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06682728 2026-04-30
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
University of California, Irvine
Phase 2 Recruiting
NCT05581589 2026-04-27
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
Phase 2 Terminated
NCT05327530 2026-04-24
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
EMD Serono
Phase 2 Active not recruiting
NCT05226117 2026-03-27
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
IRCCS San Raffaele
Phase 2 Completed
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT06133517 2026-03-16
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Fundación para el Progreso de la Oncología en Cantabria
Phase 2 Active not recruiting
NCT06528483 2024-07-30
preSAVE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting